← Leaderboards
Mandana Khalili
University Of California San Francisco
$12,345,266
Attributed
$23,082,600
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,082,600 · 9
By mechanism
U01$13,276,767 · 2
R01$5,761,284 · 2
K24$1,862,464 · 1
T32$1,340,886 · 1
K23$609,546 · 1
R03$149,720 · 1
Top collaborators
- Norah A. Terrault13 shared
- Nathalie Bzowej7 shared
- Bilal Hameed7 shared
- Stewart Cooper6 shared
- Derek D. Satre6 shared
- Jacquelyn J. Maher4 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Vivek Bhalla$6,403,326
Others in their field
Top investigators on “Risk Factors”
- Jeffrey P Krischer · University Of South Florida$393,499,152
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard Webby · St. Jude Children'S Research Hospital$180,330,417
- John M Lachin · George Washington University$139,236,598
Research focus
Risk FactorsLiverPathogenesisAffectResponseUnited StatesPersonsLiver DiseasesResearch PersonnelCirrhosisUniversitiesChronic Liver DiseaseMeasurementSan FranciscoViralPrimary Carcinoma Of The Liver CellsPopulations At RiskUnited States National Institutes Of HealthDiabetes MellitusLinkClinical ResearchClinical TrialsRandomizedCalifornia
Grant awards (54)
Impact of the COVID-19 pandemic on patient outcomes, telehealth care delivery, and treatment for unhealthy alcohol use in vulnerable patients with advanced liver disease across two healthcare systems$707,715
R01 · FY2025 · AA · contact PI
NRSA Hepatology Training Grant$431,703
T32 · FY2025 · DK
Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies$393,424
U01 · FY2025 · DK · contact PI
Impact of the COVID-19 pandemic on patient outcomes, telehealth care delivery, and treatment for unhealthy alcohol use in vulnerable patients with advanced liver disease across two healthcare systems$698,400
R01 · FY2024 · AA · contact PI
Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies$430,000
U01 · FY2024 · DK · contact PI
Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies$393,577
U01 · FY2024 · DK · contact PI
NRSA Hepatology Training Grant$354,720
T32 · FY2024 · DK
Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies$735,995
U01 · FY2023 · DK · contact PI
Impact of the COVID-19 pandemic on patient outcomes, telehealth care delivery, and treatment for unhealthy alcohol use in vulnerable patients with advanced liver disease across two healthcare systems$698,935
R01 · FY2023 · AA · contact PI
NRSA Hepatology Training Grant$308,954
T32 · FY2023 · DK
Mentoring Multidisciplinary Patient-Oriented Research in Liver Disease$193,511
K24 · FY2023 · AA · contact PI
Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies$707,682
U01 · FY2022 · DK · contact PI
Impact of the COVID-19 pandemic on patient outcomes, telehealth care delivery, and treatment for unhealthy alcohol use in vulnerable patients with advanced liver disease across two healthcare systems$699,007
R01 · FY2022 · AA · contact PI
NRSA Hepatology Training Grant$245,509
T32 · FY2022 · DK
Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies$205,325
U01 · FY2022 · DK · contact PI
Mentoring Multidisciplinary Patient-Oriented Research in Liver Disease$193,511
K24 · FY2022 · AA · contact PI
Impact of the COVID-19 pandemic on patient outcomes, telehealth care delivery, and treatment for unhealthy alcohol use in vulnerable patients with advanced liver disease across two healthcare systems$708,716
R01 · FY2021 · AA · contact PI
Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies$392,962
U01 · FY2021 · DK · contact PI
Mentoring Multidisciplinary Patient-Oriented Research in Liver Disease$193,511
K24 · FY2021 · AA · contact PI
Impact of the COVID-19 pandemic on patient outcomes, telehealth care delivery, and treatment for unhealthy alcohol use in vulnerable patients with advanced liver disease across two healthcare systems$4,974
R01 · FY2021 · AA · contact PI
Mentoring Multidisciplinary Patient-Oriented Research in Liver Disease$193,511
K24 · FY2020 · AA · contact PI
Hepatitis B Research Network (HBRN): Natural History and Treatment Studies$742,927
U01 · FY2019 · DK · contact PI
Mentoring Multidisciplinary Patient-Oriented Research in Liver Disease$193,511
K24 · FY2019 · AA · contact PI
Hepatitis B Research Network (HBRN): Natural History and Treatment Studies$164,266
U01 · FY2019 · DK · contact PI
Hepatitis B Research Network (HBRN): Natural History and Treatment Studies$1,361,363
U01 · FY2018 · DK · contact PI
Hepatitis B Research Network (HBRN): Natural History and Treatment Studies$1,018,572
U01 · FY2017 · DK
Mentoring Multidisciplinary Patient-Oriented Research in Viral Hepatitis$180,062
K24 · FY2017 · AA · contact PI
Hepatitis B Research Network (HBRN): Natural History and Treatment Studies$1,031,384
U01 · FY2016 · DK
Mentoring Multidisciplinary Patient-Oriented Research in Viral Hepatitis$180,062
K24 · FY2016 · AA · contact PI
Hepatitis B Research Network (HBRN): Natural History and Treatment Studies$884,648
U01 · FY2015 · DK
Mentoring Multidisciplinary Patient-Oriented Research in Viral Hepatitis$180,062
K24 · FY2015 · AA · contact PI
Defining Natural History and Optimal Treatment Outcome for Chronic HBV Infection$980,932
U01 · FY2014 · DK
Mentoring Multidisciplinary Patient-Oriented Research in Viral Hepatitis$174,661
K24 · FY2014 · AA · contact PI
Defining Natural History and Optimal Treatment Outcome for Chronic HBV Infection$1,026,532
U01 · FY2013 · DK
Mentoring Multidisciplinary Patient-Oriented Research in Viral Hepatitis$180,062
K24 · FY2013 · AA · contact PI
Defining Natural History and Optimal Treatment Outcome for Chronic HBV Infection$1,005,626
U01 · FY2012 · DK
Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos$428,949
R01 · FY2012 · DK · contact PI
Defining Natural History and Optimal Treatment Outcome for Chronic HBV Infection$603,522
U01 · FY2011 · DK
Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos$434,878
R01 · FY2011 · DK · contact PI
Defining Natural History and Optimal Treatment Outcome for Chronic HBV Infection$657,358
U01 · FY2010 · DK
Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos$458,229
R01 · FY2010 · DK · contact PI
Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos$463,500
R01 · FY2009 · DK · contact PI
Defining Natural History and Optimal Treatment Outcome for Chronic HBV Infection$391,518
U01 · FY2009 · DK
Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos$457,981
R01 · FY2008 · DK · contact PI
Defining Natural History and Optimal Treatment Outcome for Chronic HBV Infection$149,154
U01 · FY2008 · DK
Insulin Resistance in HCV Infection$121,674
K23 · FY2006 · DK · contact PI
HCV-induced alterations in glucose metabolism$73,970
R03 · FY2006 · DK · contact PI
Insulin Resistance in HCV Infection$121,674
K23 · FY2005 · DK
HCV-induced alterations in glucose metabolism$75,750
R03 · FY2005 · DK
INSULIN RESISTANCE IN HCV INFECTION$38,496
M01 · FY2005 · RR
Insulin Resistance in HCV Infection$121,674
K23 · FY2004 · DK
INSULIN RESISTANCE IN HCV INFECTION$43,437
M01 · FY2004 · RR
Insulin Resistance in HCV Infection$122,850
K23 · FY2003 · DK
Insulin Resistance in HCV Infection$121,674
K23 · FY2002 · DK